title: Ginsenoside Rg1 as a Promising Adjuvant Agent for Enhancing the Anti-cancer Functions of Granulocytes Inhibited by Noradrenaline
design: Granulocytes from participant 4, 5, and 6 mixed to form NA+Rg1 2. Granulocytes in NA + Rg1 1 were first treated with ginsenoside Rg1 (100 mg/L) for 12 h, then treated with ginsenoside Rg1 (100 mg/L) and NA (50 g/L) for an additional 12 h at 37 C.